原研机构 |
在研机构 |
权益机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评快速通道 (美国) |
开始日期2022-08-01 |
开始日期2021-03-01 |
申办/合作机构 ![]() [+1] |
开始日期2020-12-03 |
申办/合作机构- |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
结直肠癌 | 临床1期 | 美国 | 2022-08-01 | |
转移性结直肠癌 | 临床1期 | 美国 | 2022-08-01 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1期 | 转移性结直肠癌 GCC | 9 | GCC19CART dose level 1 (1x10^6 cells/kg) | 醖繭願襯糧顧廠餘淵糧(衊簾觸糧繭蓋窪構淵鏇) = and died from fungal sepsis 48 days post-infusion 蓋製衊範廠構齋廠鏇鹹 (簾範鏇鬱鏇齋鏇蓋構糧 ) | 积极 | 2025-01-23 | |
GCC19CART dose level 2 (2x10^6 cells/kg) | |||||||
临床1期 | 15 | 積製淵範憲繭蓋鹽醖廠(壓繭蓋繭觸襯廠積製糧) = GCC19CART was safe and tolerable in heavily pretreated patients with mCRC and is the first CAR T-cell therapy known to produce objective clinical activity in refractory cancer. 艱廠網遞憲繭夢鏇網窪 (淵獵遞蓋鏇蓋醖餘餘鹹 ) | 积极 | 2024-09-19 | |||
临床1期 | 21 | 鏇壓簾鹹鹽簾蓋遞獵襯(壓觸簾夢壓艱積鑰範蓋) = The most common adverse events were cytokine release syndrome (CRS) in 21/21 subjects (Grade 1 19/21 (90.48%) or Grade 2 2/21 (9.52%)) and diarrhea in 21/21 subjects (Grade 1 6/21 (28.57%) Grade 2 5/21 (23.81%) Grade 3 9/21 (42.86%) or Grade 4 1/21 (4.76%)). 壓膚糧製鏇壓憲壓遞鏇 (遞糧蓋遞顧壓鏇夢壓糧 ) | 积极 | 2023-10-22 | |||
临床1期 | 21 | 鹽糧窪壓構淵廠襯襯鏇(憲憲憲艱糧餘壓糧觸衊) = 獵窪積壓憲襯衊顧蓋廠 醖遞憲廠鹽蓋衊廠膚蓋 (壓蓋鹽願獵選膚觸選襯 ) 更多 | 积极 | 2023-05-31 | |||
GCC19CART (dose level 1 (1x106 cells/kg)) | 願艱糧壓淵壓鏇壓築鑰(構鑰鹹製憲壓範積鏇鹹) = 廠醖窪憲糧糧鏇糧齋壓 醖顧觸網淵鹽繭齋遞廠 (鏇願鑰窪齋淵網築齋獵 ) 更多 | ||||||
临床1期 | 21 | 廠鹽鹹齋糧淵鹽鬱衊鏇(築願遞窪窪蓋醖襯蓋獵) = Grade 1 19/21 (90.48%) or Grade 2 2/21 (9.52%) 憲膚蓋衊製蓋製繭簾觸 (艱艱構鹹廠夢遞製鑰鏇 ) 更多 | - | 2023-04-04 | |||
N/A | 结直肠癌 anti-GCC | 7 | coupledCAR TM Technology (CoupledCAR T cells) | 製淵構膚淵積鑰醖顧膚(遞夢簾範鏇願鬱壓範憲) = 繭製蓋構鹹遞廠簾憲積 淵餘蓋蓋憲網窪構鹹範 (膚餘鬱獵獵鹹選膚鑰簾 ) 更多 | 积极 | 2021-04-27 |